Irritable Bowel Syndrome (IBS) is a common gastrointestinal disorder affecting 10 — 20 per cent of people. Abdominal pain, bloating and altered bowel habit significantly affect patient’s quality of life and can force them to take days off work.

Previous research (the ACTIB trial) led by Professor Hazel Everitt at the University of Southampton in collaboration with researchers at King’s College London, showed that that Cognitive Behavioural Therapy (CBT) tailored specifically for IBS and delivered over the telephone or through an interactive website is more effective in relieving the symptoms of IBS than current standard care one year after treatment.

This 24 month follow up research published in Lancet Gastroenterology and Hepatology this week has shown that benefits continue two years after treatment despite patients having no further therapy after the initial CBT course. These results are important as previously there was uncertainty whether the initial benefits could be sustained in the long term. Currently there is limited availability of CBT for IBS in a resource constrained NHS but this research indicates that easily accessible treatment could be provided to a large number of patients and provide them with effective, long-term relief.

Professor Everitt added: “the fact that both telephone and web based CBT sessions were shown to be effective treatments is a really important and exciting discovery. Patients are able to undertake these treatments at a time convenient to them, without having to travel to clinics and we now know that the benefits can last long term.”



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Explore More

Inflammatory bowel disease increases risks for pregnant women

Pregnant women with inflammatory bowel disease (IBD) and their babies face increased risks and complications compared to pregnant women without IBD. Those are the findings from a new University of

Pancreatic cancer immune map provides clues for precision treatment targeting

Pancreatic cancer patients may benefit from future precision treatments as a new study shows how some tumours may potentially be more susceptible to macrophage-based therapies. The study which is published

Discovery of a circovirus involved in human hepatitis

Scientists from the Institut Pasteur, Necker-Enfants Malades Hospital (AP-HP), Inserm in the Imagine Institute, Université Paris Cité and the Alfort National Veterinary School (EnvA) have identified a previously unknown species